However, data with zetomipzomib in lupus nephritis are not quite as good as they first appear.
GSK takes on arthritis and Roche aims for convenience, while Pfizer is set to report infant pneumococcal vaccine data.
Omicron-adapted boosters look good ahead of a key FDA panel, but will the virus soon outmanoeuvre them?
Pivotal data will show whether KarXT can walk the risk-benefit tightrope.
A look at blockbuster origins shows the role of external innovation, but more of these huge franchises are in the hands of their inventors than ever before.
A surprise move into the Car-T space suggests the beleaguered Belgian biotech still has an eye on its rich benefactor.
Real-world data on Translarna look good, but with a failed confirmatory trial and a troubled history US approval is far from guaranteed.